Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Isolation of alpha-linolenic acid from Sutherlandia frutescens and its inhibition of Mycobacterium tuberculosis’ shikimate kinase enzyme

  • Peter Masoko1Email author,
  • Itumeleng H. Mabusa1 and
  • Rachmond L. Howard2
BMC Complementary and Alternative MedicineBMC series – open, inclusive and trusted201616:366

https://doi.org/10.1186/s12906-016-1344-1

Received: 2 December 2015

Accepted: 8 September 2016

Published: 17 September 2016

Abstract

Background

Sutherlandia frutescens (L) R.Br. is one of traditional herbal medicines that formed the basis of primary health care systems since the earliest days and is still widely used. Sutherlandia is prescribed for people with tuberculosis (TB), but is still not known which compound(s) acts against M. tuberculosis and its mode of action. The aim of this study was to identify and isolate antimycobacterial compounds from S. frutescens extracts against shikimate kinase, a drug target for M. tuberculosis.

Methods

S. frutescens were dried, ground and extracted with ethanol, dichloromethane: methanol and water. Fractionation and separation of compounds was done with column chromatography. Chromatograms were developed in butanol/acetic acid/water (BAW) [21:6:3]; chloroform/methanol/water/formic acid (CMWF1) [60:15:2:1] and (CMWF2) [21:9:1:0.3]. Separation and isolation of active compounds were done using preparative HPLC. The activity of the plant extracts were also screened against shikimate kinase enzyme (MtbSK) using the MtbSK inhibition assay.

Results

The DCM: MeOH (1:1) extract showed a high percentage inhibition (with an IC50 of 0.1 μg/ml) of MtbSK and the purified inhibitor was an Alpha-Linolenic Acid (ALA) compound and it had a significant IC50 of 3.7 μg/ml.

Conclusions

This study demonstrated that ALA from S. frustescens is an inhibitor of shikimate kinase a good drug target for M. tuberculosis.

Keywords

Sutherlandia frutescens Mycobacterium tuberculosis Shikimate kinase

Background

Sutherlandia frutescens (L) R.Br. is one of traditional herbal medicines that formed the basis of primary health care systems since the earliest days and is still widely used [1]. S. frutescens contains several essential, bioactive compounds with clinically proven pharmacological activities [24]. This makes the plant attractive as a medicine for various ailments and diseases. Sutherlandia is recommended by the South African Department of Health as a supporting treatment for people living with Acquired Immune Deficiency Syndrome (AIDS) as immune system booster [5, 6]. It is also prescribed for treatment of cancer, tuberculosis (TB), diabetes, anxiety and clinical depression [68]. TB is a highly infectious disease caused by Mycobacterium tuberculosis and it kills millions of people annually. It is also one of the common co-infections in people living with HIV/AIDs thus worsening the HIV/AIDS pandemic.

New drugs with novel mechanisms of action are needed to avoid the cross-resistance problem and more importantly to kill persister TB populations [9]. Advances in molecular tools make it possible for identification of targets essential for survival and persistence whose inhibition is likely to shorten therapy. A study done by Zhang, [10] reviewed various new drug targets and drug candidates; among these was the enzyme shikimate kinase. Shikimate kinase is the fifth enzyme in the shikimate biosynthetic pathway from M. tuberculosis. This enzyme is considered an excellent target for developing novel anti-tuberculosis agents as the pathway in which it is involved only takes place in microbes and some plants but is absent in mammals [11]. The shikimate pathway involves seven enzymatic steps in the biosynthesis of chorismate end product, which in turn serves as the precursor for the synthesis of the aromatic amino acids, folates, uniquinones, mycobactins, menaquinones and napthoquinones [12]. The importance of this pathway has been proven in culture using mutants whose growth is completely inhibited without the provision of aromatic supplements [13]. This study was aimed at investigating the activity of S. frutescens extracts against Mycobacterium tuberculosis shikimate kinase enzyme (MtSK).

At the same time this research seeks to discover new drugs from S. frutescens and hence contribute to the fight against TB. There is little scientific data on the activity on S. frutescens against TB. The only data available is mainly from personal communications and laboratory reports, on the use of S. frutescens plant extract for support treatment in patients suffering from TB. The wide use of Sutherlandia in traditional medicine and these preliminary findings suggest that S. frutescens is a good candidate for discovery of new anti-mycobacterial drugs which can be used for treatment of TB.

Methods

Plant collection

About 1 kg of fresh aerial parts (the leaves and stems) of Sutherlandia were collected at a community-based farm in Petrusburg in the Free State, South Africa (29° 6.774′ S; 25° 24.305′ E; 1249 m above sea level). A twig containing a flower was sent to the South African National Biodiversity Institute (SANBI) for identification (SANBI voucher specimen number: 428679). The plant material was finely ground and stored at a room temperature until tests were done.

Extraction procedure

Plant material extraction based on the traditional method

Dried ground aerial parts (leaves and stems) of S. frutescens (50 g) were boiled in 2 L of distilled water using a hot plate and a steel extraction vessel covered with an aluminium foil, it was stirred occasionally. The suspension was then removed from the hot plate, cooled in room temperature and filtered through Whatman no.1 filter paper and collected in a glass beaker. The aqueous extraction was freeze-dried and a powder was subsequently obtained. The extract was stored in an airtight container in the cold room at 4 °C until further testing.

Plant material extractions using organic solvents

The dried and ground aerial parts of the plant (100 g) were separated into 2 times 50 g each. One litre of 96 % Ethanol was added to 50 g plant material stirred and left overnight. The suspension was filtered the following day using Whatman no.1 filter paper and evaporated to give an ethanol extract (excess ethanol from the Whatman no.1 extract was dried using a fume-hood overnight). The remaining 50 g plant material was used to prepare 1:1 dichloromethane: methanol (DCM:MeOH; 1.4 L) extract. The same procedure used to prepare the ethanol extract was used to prepare the DCM:MeOH; 1:1 extract.

Shikimate kinase enzyme inhibition assay

A purified shikimate kinase enzyme was obtained from Prof Kenyon at The Council for Scientific and Industrial Research (CSIR) in South Africa and stored at −80 °C was used for the assay and the stock solution was prepared as per the Table 1.
Table 1

Stock solution for assay

 

Stock solution concentration (mM)

Volume (μl)

Final concentration (mM)

K-PO4 buffer, pH 6.8

250

4760.0

100

MgCl2

60

39.7

0.2

ATP

60

39.7

0.2

Inhibitor

12

991.7

1

KCl

100

1190.0

10

Shikimic acid

100

238.0

2

Enzyme/dH20(nM)

100

1785.0

15

nH2O

 

2856.0

 
The stock solution containing everything excluding the inhibitor (extracts or fractions) and the ATP was prepared. Extracts/fractions were weighed out to a concentration of 10 mg/ml. Six Eppendorfs were prepared with 1:10 increasing dilution of the extract/fraction. To each Eppendorfs 319 μl of stock solution was added plus the 25 μl of the inhibitor at each concentration. To the blank 25 μl of nH2O was added and 1.3 μl of 200 mM EDTA was also added to this tube as a stopping reagent. To the rest of the tubes having reaction mixtures and also to the blank 1.4 μl of 60 mM ATP was added, vortexed and incubated for 15 min. HPLC vials were then lined up, labeled and 319 μl was distributed into each triplicates. The reaction was started by the addition of 1 μM concentration of the enzyme. The assay was done at 37 °C for 15 min. The reaction was terminated by the addition of 2.5 μl 200 mM EDTA. The samples were centrifuged for 2 min at 13,000 rpm and the ADP and ATP concentrations were determined by HPLC. The shikimate kinase inhibition assay is based on quantification of dissociated ADP from the ATP molecule after its phosphate group has been transferred to shikimate as shown on Fig. 1. The IC50 for the extracts or fractions were determined by plotting and evaluating the data using Graph Pad prism software, version 5.0. There are no positive controls of known approved shikimate kinase inhibitors used to compare the obtained results with because this study was the first using this approach.
Fig. 1

The fifth step of the shikimate pathway (http://en.wikipedia.org/wiki/Shikimate_kinase)

Fractionation of extracts using column chromatography

The solvent-solvent fractionation was selected to simplify extracts by fractionating the chemical compounds into broad groups based on their solubility. The fractions collected were concentrated using the rotary evaporator (Buchi Rotavapor) under reduced pressure, rotating at 100 rpm and with water bath at 40 °C. The fractions were phytochemically analyzed using TLC. The separated components were visualized with ultraviolet light (360 nm); the plates were sprayed with vanillin-sulphuric acid reagent and heated at 110 °C for colour development.

Fractionation of the plant extracts was done as follows:

DCM: MeOH 1:1 and ethanol extracts

One gram of each extract was dissolved in 100 % DCM, mixed with silica gel and placed in a warm water bath until it has dried up. A column was packed with 118 g silica gel and 100 % DCM was used to dissolve the silica gel and fractions were eluted as follows:
  • Fraction 1 with 100 % DCM yields A

  • Fraction 2 with 30 % MeOH/DCM yields B

  • Fraction 3 with 70 % MeOH/DCM yields C

  • Fraction 4 with 100 % MeOH yields D

H2O extract

One gram was dissolved in 100 % MeOH and mixed with silica gel and placed in warm water bath until it has dried up. A column was packed with 120 g silica gel dissolved in 100 % MeOH and fractions were eluted as follows:
  • Fraction 1 with 30 % DCM/acetone yields E

  • Fraction 2 with 100 % ethylacetate yields F

  • Fraction 3 and 4 with 100 % MeOH yields both G and H

All collected fractions were left to dry overnight under the fume hood. The fractions with the compound(s) of interest were pooled and preparative HPLC was run for further fractionation and further bioassays.

Using preparative HPLC to separate the combined fractions A&B

The DCM: MeOH fractions A and B produced in section 2.4 were combined to yield a mass of 2.381 g. A 100 mg of these were dissolved in 5 ml methanol. Two HPLC pumps shown on Tables 2 and 3 below were used. A total of 20 sub-fractions were collected and these 20 sub-fractions were assayed against M. tuberculosis shikimate kinase enzyme. The most active sub-fraction was found to be sub-fraction 8.
Table 2

Gradient Table for Load pump

Time (min)

Flow (mL/min)

%A IPA

%B MeOH

%C HOH

%D CAN

0.0

1.0

0

100

0

0

25.0

1.0

0

50

0

50

30.0

1.0

0

0

0

100

31.0

1.0

100

0

0

0

38.0

1.0

100

0

0

0

40.0

1.0

0

100

0

0

50.0

1.0

0

100

0

0

Table 3

Gradient Table for Gradient Pump

Time (min)

Flow (mL/min)

% HOH

% MeOH

% 0.1 % FA HOH

% CAN

0.0

5.5

0

65

35

0

2.0

5.5

0

65

35

0

15.0

5.5

0

75

12

13

25.0

5.5

0

0

0

100

40.0

5.5

0

0

0

100

44.0

5.5

0

65

35

0

50.0

5.5

0

65

35

0

Column heater temperature: 60 °C

PDA: Scanning 210–600 nm

Collection: Hold time: 1 min, 2 min collection intervals for 20 vials

Results and discussion

The shikimate enzyme is one of the most vital enzymes involved in the metabolic pathways of Mycobacterium tuberculosis. The principle of the shikimate kinase inhibition assay is primarily based on the enzyme shikimate kinase phosphorylating shikimic acid to form shikimate-3-phosphate and a resultant ADP as shown in Fig. 1. In the presence of a good inhibitor less or none of this resultant ADP will be produced, an appropriate inhibitor would bind where a phosphate is supposed to bind on the shikimic acid and therefore subsequently restricting its phosphorylation and hence producing no ADP. The strongest inhibitor produces less ADP. After performing a series of shikimate kinase inhibition assays on the crude extracts it was noticed that the DCM: MeOH 1:1 extract was showing more potential in terms of inhibition of the shikimate kinase enzyme’s activity and hence had a fairly low average of ADP produced and also as seen on Table 4 had an IC50 of 0.1 ug/ml (Fig. 2) which was lower than the H2O (5.1 ug/ml) (Fig. 3) and the ethanol (1.7 ug/ml) extracts (Fig. 4). This realization led to the decision to performing more tests with this extract.
Table 4

IC50 values of all the extracts, fractions and sub fractions

Sample name

IC50 value (μg/ml)

S. frutescens crude extracts (January)

 H2O

5.1

 EtOH

1.7

 DCM: MeOH 1:1

0.1a

DCM: MeOH 1:1 fractions

 fraction A

2.5a

 fraction B

0.3a

 fraction C

1.5

 fraction D

94.3

aThe extract or fraction was chosen for further analysis

Fig. 2

Effect of the DCM: MeOH 1:1 extract on the IC50

Fig. 3

Effect of the H2O extract on the IC50

Fig. 4

Effect of the EtOH extract on the IC50

Percentage inhibition obtained from single point inhibitions of the 20 sub-fractions produced via preparative HPLC. Sample 1,13,14,18 and 20 shows almost 100 % inhibition while sample 7 has almost 0 % inhibition against shikimate kinase (Fig. 5). Of the 20 sub-fractions that were collected, sub-fraction 8 was shown to be one of the most active against the shikimate kinase enzyme (Fig. 6), hence the decision to pursue its isolation and characterization. Figure 6 shows that at just after 10 min, a large peak of a compound (sub-fraction 8) with a molecular ion peak at (m/z) 277.4 was collected and this compound ionized in the negative electrospray ionization (ES-). This compound had a bright yellow colour and was sticky upon evaporation with the rotavap. The TLC plate on Fig. 7 also showed a single band, meaning that separation did occur and that a single compound was found in this sub-fraction 8. The most useful tool in identification of a compound in chemistry is the SDBS assimilations software; this software was very helpful in determining the structure and molecular formula of the isolated compound by using its proton and carbon NMR spectra (Table 5). The protons and the carbons of the isolated compound exactly matched those assimilated with from the software hence the software was able to identify the compound’s chemical formula as C18H30O2 giving a total molecular mass of 278 u.
Fig. 5

Chart representing percentage inhibition of the single point inhibitions of the 20 sub-fractions produced via preparatory HPLC

Fig. 6

Dose response curve determining the IC50 of sub-fraction 8 from the fractionation of fractions A&B of the June DCM: MeOH 1:1 extract

Fig. 7

TLC plates developed in different mobile phases. The TLC plates were sprayed with 0.1 % vanillin-sulphuric acid. From left to right, the first four lanes represent the H2O fractions, the next four lanes represent EtOH fractions and the last four lanes represent DCM:MeOH (1:1) fractions

Table 5

Spectroscopic data of the SDBS ALA assimilations and the NMR from sub-fraction 8

13C

SDBS

Sub-fraction 8

1

180.55

 

2

131.94

131.97

3

130.23

130.25

4

128.30

128.30

5

128.30

128.26

6

127.84

127.76

7

127.19

127.13

8

34.17

34.01

9

29.63

29.56

10

29.19

29.14

11

29.13

29.07

12

29.13

29.04

13

27.26

27.17

14

25.68

25.62

15

25.60

25.54

16

24.72

24.72

17

20.61

20.54

18

14.30

14.24

Its IUPAC name and structure were determined using Chem Draw ultra 8 software and these are represented on Fig. 8. The IUPAC name of the isolated compound was found to be (9Z, 12Z, 15Z)-octadeca-9,12,15-trienoic acid and its common name is alpha linolenic acid. IC50 of the compound was also determined and recorded to be 3.7 ug/ml (Fig. 9). Alpha-linolenic (ALA) is an essential omega-3 fatty acid that cannot be synthesized by the human body and hence has to be supplied by dietary sources such as fish, plants, walnuts, grape seed (canola), several legumes, flaxseed, and green leafy vegetables and vegetable oils [14, 15] but has not been reported to have been isolated from S. frutescens before. Stark et al. [14] mentioned that potential benefits of ALA include cardio-protective effects, modulation of the inflammatory response, and a positive impact on both central nervous system function and behavior. According to Stark et al. [14], as a result of many studies they have conducted in their study, ALA is not only essential for dietary requirements but also has therapeutic properties. Several studies have proven amongst other free fatty acids that alpha linolenic acid is active against a wide range of microorganisms including bacteria such as S. aureus and Bacillus subtilis [16], Helicobacter pylori, [17] viruses such as hepatitis C virus (HCV) [18] and fungi such as Rhizoctonia solani and Crinipellis perniciosa [19]. According to Desbois and Smith, [20] their antibacterial mode of action is not clearly understood but may also result from the inhibition of enzyme activity, impairment of nutrient uptake, generation of peroxidation and auto-oxidation degradation products or direct lysis of bacterial cells. The broad spectrum of activity they possess, the non-specific mode of action and their safety makes them attractive as antibacterial agents for various applications in medicine, agriculture and food preservation.
Fig. 8

Structure of the isolated compound (sub-fraction 8) and its IUPAC name

Fig. 9

IC50 data of ALA from the DCM: MeOH 1:1 extract’s fractions

This is a novel study. Firstly, this is the first report on identifying ALA from S. frutescens. Secondly, this is the first report showing ALA from S. frutescens inhibiting shikimate kinase enzyme, an important drug target for M. tuberculosis. Thirdly, this is the first time that ADP quantification method for shikimate kinase inhibition assay using HPLC was used. In other words, a reliable HPLC based M. tuberculosis shikimate kinase inhibition assay was developed in this study. Several studies have used liquid chromatography-Mass spectrometry (LC-MS) to determine M. tuberculosis shikimate kinase enzyme activity by quantifying shikimate-3-phosphate which is a resulting product of the phosphorylation of shikimate [2123]. The advantage of using the ADP method is that one can see the viability of the enzyme by tracing the production of ADP thus using the HPLC machine not only ensures the collection of qualitative data but also the quantitative data. The ADP method used in this study could be useful for scientists to study other potential M. tuberculosis shikimate kinase inhibitors. Kinases have a conserved phosphoryl transfer mechanism [2426] thus to find a unique inhibitor and a way of determining inhibition of kinases advance kinases kinetic studies.

Conclusion

In conclusion, this study demonstrated that ALA from S. frustescens is an inhibitor of shikimate kinase a good drug target for Mycobacterium tuberculosis. Further studies to test the isolated compound, ALA on whole M. tuberculosis cells will be conducted.

Abbreviations

AIDS: 

Acquired immune deficiency syndrome

ALA: 

Alpha-linolenic acid

BAW: 

Butanol/acetic acid/water

CMWF: 

Chloroform/methanol/water/formic acid

HPLC: 

High performance liquid chromatography

IUPAC: 

International Union of pure and applied chemistry

MtbSK: 

Shikimate kinase enzyme

TLC: 

Thin layer chromatography

Declarations

Acknowledgements

The authors thanks Dr R.M. Mampa of the Chemistry department and Dr L.K. Mdee of the Pharmacy department for their assistance with structural elucidation.

Funding

We would like to thank the CSIR and NRF (Reference: IFR1203260814; Grant No: 81341 and University of Limpopo (Grant no: 640) for financial support.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Authors’ contributions

PM and RH, conception and design of the study. IM carried out the experiments and analysed the data. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo
(2)
University of Mpumalanga

References

  1. Wilkinson D, Gcabashe L, Lurie M. Traditional healers as tuberculosis treatment supervisors: precedent and potential. Int J Tuberc Lung Dis. 1999;3:838–42.PubMedGoogle Scholar
  2. Prevoo D, Swart P, Swart AC. The influence of Sutherlandia frutescens on adrenal steriodogenic cytochrome P450 enzymes. J Ethnopharmacol. 2008;118:118–26.View ArticlePubMedGoogle Scholar
  3. Haraguchi H. Antioxidant plant constituents in bioactive compounds from natural sources- isolation, characterisation and biological properties. London: Taylor and Francis; 2001.Google Scholar
  4. Ojewole JAO. Anticonvulsant property of Sutherlandia frutescens (Fabaceae) shoots aqueous extract. Brain Res Bull. 2008;75:126–32.View ArticlePubMedGoogle Scholar
  5. Seier JV, Mdhluli M, Dhansay MA, Loza J, Laubscher R. A toxicity study of Sutherlandia leaf powder (Sutherlandia frutescens sub-species microphylla) consumption. Tygerberg: Medical Research Council; 2002.Google Scholar
  6. SA Healthinfo. Traditional medicines. Sutherlandia frutescensherba. Available: http://www.sahealthinfo.org/traditionalmeds/monographs/sutherlandia.htm (2009). (Accessed 10 May 2012).
  7. Mills E, Cooper C, Seely D, Kanfer I. African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. J Nutr. 2005;4:19.View ArticleGoogle Scholar
  8. van Wyk BE. Medicinal plants of South Africa. Pretoria: Briza Publishers; 1997. p. 246–7.Google Scholar
  9. Zhang X, Zhang S, Hao F. Expression, purification and properties of shikimate dehydrogenase from Mycobacterium tuberculosis. J Biochem Mol Biol. 2005;38(5):624–31.View ArticlePubMedGoogle Scholar
  10. Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther. 2007;82:595–600.View ArticlePubMedGoogle Scholar
  11. Gu Y, Reshetnikova L, Li Y, Wu Y, Yan H, Singh S, Ji X. Crystal structure of shikimate kinase from Mycobacterium tuberculosis reveals the dynamic role of LID Domain in catalysis. J Mol Biol. 2002;319:779–89.View ArticlePubMedGoogle Scholar
  12. Kapnick SM, Zhang Y. New development: targeting the shikimate pathway. Expert Opin Drug Discovery. 2008;3:565–77.View ArticleGoogle Scholar
  13. Parish T, Stoker NG. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology. 2005;146:1969–75.View ArticleGoogle Scholar
  14. Stark AH, Crawford MA, Reifen R. Special article: Update on alpha-linolenic acid. Nutr Rev. 2008;66:326–32.View ArticlePubMedGoogle Scholar
  15. Brouwer IA, Katan MB, Zock PL. Dietary α-Linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk; A meta-analysis1,2. J Nutr. 2004;134:919–22.PubMedGoogle Scholar
  16. McGaw LJ, Jäger AJ, van Staden J. Antibacterial effects of fatty acids and related compounds from plants. S Afr J Bot. 2002;68:417–23.View ArticleGoogle Scholar
  17. Obonyo M, Zhang L, Thamphiwatana S, Pornpattananangkul D, Fu V, Zhang L. Antibacterial activities of Liposomal linolenic acids against antibiotic-resistant helicobacter pylori. Mol Pharm. 2012;9:2677–85.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Leu G, Lin T, John TA. Anti-HCV activities of selected polysaturated fatty acids”. Biochem Biophys Res Commun. 2004;318:275–80.View ArticlePubMedGoogle Scholar
  19. Walters D, Raynor L, Mitchell A, Walker R, Walker K. Antifungal activities of four fatty acids against plant pathogenic fungi. Mycopathologia. 2004;157:87–90.View ArticlePubMedGoogle Scholar
  20. Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl Microbiol Biotechnol. 2010;85:1629–42.View ArticlePubMedGoogle Scholar
  21. Mulabagal V, Calderon AI. Development of an ultrafiltration-liquid chromatography/mass spectrometry (UF-LC/MS) based ligand-binding assay and LC/MS based functional assay for Mycobacterium tuberculosis shikimate kinase. Anal Chem. 2010;82:3616–21.View ArticlePubMedGoogle Scholar
  22. Krell T, Coggings JR, Lapthorn AJ. The three-dimensional structure of shikimate kinase. J Mol Biol. 1998;278:983–97.View ArticlePubMedGoogle Scholar
  23. Simithy J, Reeve N, Hobrath JV, Reynolds RC, Calderon AI. Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS. Tuberculosis. 2014;94:152–8.View ArticlePubMedGoogle Scholar
  24. Kenyon CP, Roth RL, van der Westhuyzen CW, Parkinson CJ. Conserved phosphoryl transfer mechanisms within kinase families and the role of the C8 proton of ATP in the activation of phosphoryl transfer. BMC Res Notes. 2012;5:131.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Hartman MD, Bourenkov GP, Oberschall A, Strizhov N, Bartunik HD. Mechanism of phosphoryl transfer catalysed by shikimate kinase from Mycobacterium tuberculosis. J Mol Biol. 2006;364:411–23.View ArticleGoogle Scholar
  26. Matte A, Tari LW, Delbaere LTJ. Mini Review: How do kinases transfer phosphoryl groups? Structure. 1998;6:413–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement